The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2022 | Using an iPSC-derived model to understand the mechanisms driving light chain-induced cardiotoxicity
Camille Vanessa Edwards, MD, Boston University School of Medicine, Boston, MA, comments on the uses and advantages of an induced pluripotent stem cell (iPSC)-derived model to study the early mechanisms driving light chain-induced cardiotoxicity in AL amyloidosis. Using this model, it was found that there may be early cardiac hypertrophy and cardiac remodelling occuring in cardiomyoctes exposed to light chains, in addition to a downregulation in transcripts related to the adaptive immune response. Dr Edwards explains that this model can also be used to test novel therapeutics and to find new biomarkers to predict the risk of light chain-induced cardiotoxicity in patients with AL amyloidosis. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
